These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8256764)

  • 1. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group.
    Barrett RJ; Blessing JA; Homesley HD; Twiggs L; Webster KD
    Am J Clin Oncol; 1993 Dec; 16(6):494-6. PubMed ID: 8256764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
    J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
    Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
    Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
    Pierga JY; Diéras V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
    Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma.
    Long HJ; Langdon RM; Cha SS; Veeder MH; Pfeifle DM; Krook JE; Ebbert LP; Tschetter LK; Roshon SG
    Gynecol Oncol; 1995 Aug; 58(2):240-3. PubMed ID: 7622111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
    Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
    J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin.
    Deppe G; Malviya VK; Malone JM; Christensen CW; Saunders D
    Eur J Gynaecol Oncol; 1994; 15(4):263-6. PubMed ID: 7957332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
    Long HJ; Nelimark RA; Podratz KC; Suman V; Keeney GL; Nikcevich DA; Kugler JW; Rowland KM; Kardinal CG; Wos EJ
    Gynecol Oncol; 2006 Mar; 100(3):501-5. PubMed ID: 16185755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Filgrastim support during combination chemotherapy using cisplatin, doxorubicin, and cyclophosphamide to treat advanced or recurrent endometrial cancer: a clinical study and literature review.
    Hall DJ; Martin DA; Kincaid K
    Eur J Gynaecol Oncol; 2003; 24(6):481-9. PubMed ID: 14658586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.
    McMeekin DS; Sill MW; Walker JL; Moore KN; Waggoner SE; Thaker PH; Rizack T; Hoffman JS; Fracasso PM
    Gynecol Oncol; 2015 Jul; 138(1):36-40. PubMed ID: 25958319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
    J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial.
    Soper JT; Reisinger SA; Ashbury R; Jones E; Clarke-Pearson DL
    Gynecol Oncol; 2004 Oct; 95(1):95-100. PubMed ID: 15385116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
    Fleming GF; Fowler JM; Waggoner SE; Copeland LJ; Greer BE; Horowitz I; Sutton G; Schilder RJ; Fracasso PM; Ball HG; McGuire WP
    J Clin Oncol; 2001 Feb; 19(4):1021-9. PubMed ID: 11181665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.
    Fleming GF; Filiaci VL; Bentley RC; Herzog T; Sorosky J; Vaccarello L; Gallion H
    Ann Oncol; 2004 Aug; 15(8):1173-8. PubMed ID: 15277255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
    McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
    Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
    Randall ME; Filiaci VL; Muss H; Spirtos NM; Mannel RS; Fowler J; Thigpen JT; Benda JA;
    J Clin Oncol; 2006 Jan; 24(1):36-44. PubMed ID: 16330675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer.
    Yahata H; Hirakawa T; Fujita T; Ariyoshi K; Sonoda K; Amada S; Kobayashi H; Nakano H
    Int J Clin Oncol; 2004 Aug; 9(4):317-21. PubMed ID: 15375709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A pilot study of combined chemotherapy with paclitaxel, doxorubicin and cisplatin for endometrial cancer].
    Honma H; Sagae S; Terasawa K; Tanaka R; Chida M; Mizumoto H; Ishioka S; Saito T; Kudo R
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):549-53. PubMed ID: 15114698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A feasibility study of doxorubicin/cisplatin (AP) for postoperative chemotherapy in patients with advanced endometrial cancer].
    Nishio S; Katsumata N; Tanabe H; Matsumoto K; Yonemori K; Kouno T; Shimizu C; Ando M; Fujiwara Y
    Gan To Kagaku Ryoho; 2006 Nov; 33(11):1589-93. PubMed ID: 17108724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.